Charis 1000
Alternative Names: C 1K; C-2K; Charis-1000Latest Information Update: 11 Sep 2026
At a glance
- Originator Ensol Biosciences
- Class Antineoplastics; Peptides
- Mechanism of Action Phosphorylation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer; Prostate cancer
- No development reported Triple negative breast cancer
Most Recent Events
- 04 Mar 2026 Adverse events and pharmacokinetics data from a phase I trial in healthy volunteers presented at the 127th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2026)
- 28 Feb 2026 No recent reports of development identified for phase-I development in Triple-negative-breast-cancer(In volunteers) in South Korea (SC)
- 08 Oct 2025 Phase-I clinical trials in Non-small cell lung cancer (SC) (Ensol Biosciences pipeline, September 2025)